Kent-Athlone Pharma Group secured Gold EcoVadis Sustainability Rating

Kent-Athlone Pharma Group, a European Speciality Pharmaceutical company has secured a Gold Sustainability Rating from EcoVadis, following an assessment completed in December 2023.

As a company, Kent-Athlone Pharma Group is highly committed to meeting its obligations to Environmental, Social, and Corporate Governance (ESG), and in 2023 chose to undertake a rigorous external assessment performed by EcoVadis. According to EcoVadis, almost half of the top 25 pharma/biotech companies have engaged with the EcoVadis assessment methodology.

The EcoVadis assessment is described by the company as “an evaluation of how well a company has integrated the principle of sustainability/CSR into their business and management system”. EcoVadis is the world’s most trusted provider of business sustainability ratings, providing detailed assessments of business’ environmental, social, and ethical performance. Based on leading standards, such as GRI, UNGC, and ISO 26000, the rating is supervised by an international scientific committee. EcoVadis ratings have been tested on over 100,000+ companies across 200+ industries and 175+ countries.

Kent-Athlone Pharma Group, received a “Gold” Sustainability Rating in December 2023, placing the company in the top 5% of companies assessed and rated, with an “Advanced” rating received in the four EcoVadis assessment pillars of: Environment, Labour & Human Rights, Ethics and Sustainable Procurement.

“We are proud to have received a Gold Sustainability Rating, which underlines the commitment of the company, and to every one of our committed employees to high standards in everything that we do”. Terry Petersen, CEO